UBS Group’s Cellyan Biotechnology HKPD Stock Holding History

UBS Group’s Portfolio HKPD Stock Details HKPD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$411	Buy	1,081 +971	+883%	+$532	﹤0.01%	9865
2026 Q1	$63	Sell	110 -1,426	-93%	-$1.04K	﹤0.01%	10179
2025 Q4	$1.27K	Buy	1,536 +1,438	+1,467%	+$1.54K	﹤0.01%	9645
2025 Q3	$144	Sell	98 -20,777	-100%	-$26.6K	﹤0.01%	9870
2025 Q2	$26.7K	Buy	20,875 +20,603	+7,575%	+$25.5K	﹤0.01%	8248
2025 Q1	$294	Buy	+272	New	+$480	﹤0.01%	9847

Other funds holding HKPD

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

UBS Group's HKPD Position: Q2 2026 in Review

UBS Group increased its Cellyan Biotechnology (HKPD) stake by 883% in Q2 2026, buying an estimated $532 and bringing the position to 1,081 shares worth $411. The position accounts for ﹤0.01% of the portfolio, ranked #9865.

UBS Group first reported a position in HKPD in Q1 2025 and has held it in 6 quarters since. The position peaked at $26.7K in Q2 2025. 6 funds tracked by Wall St. Rank hold HKPD as of Q2 2026.

UBS Group held 1,081 shares of Cellyan Biotechnology worth $411 as of Q2 2026.
UBS Group bought 971 Cellyan Biotechnology shares in Q2 2026, an estimated $532.
Cellyan Biotechnology made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9865 holding.
UBS Group first reported a position in Cellyan Biotechnology in Q1 2025 and has held it in 6 quarters since.
UBS Group's Cellyan Biotechnology position peaked at $26.7K in Q2 2025.
6 funds tracked by Wall St. Rank held Cellyan Biotechnology as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.